Context Recent randomized controlled trials (RCTs) examined the role of adding androgen
receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide …

Management of metastatic prostate cancer has undergone a revolution over the past decade
with the introduction of several novel agents and repurposing of others. Several clinical trials …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

Abstract Background: Metastatic prostate cancer (PCa) is associated with considerable
diminished overall survival (OS). Standard treatment for metastatic PCa has long been …

Background Men with high-risk non-metastatic prostate cancer are treated with androgen-
deprivation therapy (ADT) for 3 years, often combined with radiotherapy. We analysed new …

Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies due to
the functional impairment of effector T cells and their inefficient trafficking to tumours. T-cell …

Context Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are
available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance …

Background and purpose Oligometastatic prostate cancer is a new and emerging treatment
field with only few prospective randomized studies published so far. Despite the lack of …

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in
STAMPEDE, a multiarm, multistage platform trial in men starting long‐term hormone therapy …